Peptide Library

Human study PLS-00133

Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis.

Case report · 1 participants enrolled · not included in the assessments (other)

Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Malignant thymoma associated with T-cell lymphocytosis. A case report with immunophenotypic and gene rearrangement analysis.primary · Archives of pathology & laboratory medicine · 1993-03-01 · PMID 8382915

Design and participants

Design
Case report
Population
A patient with lymphocyte-rich malignant thymoma who developed peripheral T-cell lymphocytosis after pulmonary metastases.
Conditions
Malignant thymoma, T-cell lymphocytosis
Planned enrollment (registry)
Not reported
Enrolled
1
Randomized
Not reported
Completed follow-up
Not reported

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety, and how safety was monitored isn’t described.

    The authors concluded (paraphrased): The authors suggest the lymphocytosis comes from a poorly defined immunoregulatory disorder related to the thymoma, perhaps with secondary thymic hormone imbalance. They consider a second neoplasm excluded and lymphocyte spillover unlikely.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Thymosin beta 4 was not administered; only its endogenous serum level was measured in one patient.
    • no control group: Single case report with no comparison group of any kind.
    • small or imprecise: Only one patient was described, so nothing can be generalized from it.
    • abstract only: Only the PubMed abstract is available in the record; no full text was available.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 8382915, abstract (final sentence) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 8382915, title (title, 'A case report') · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 8382915, abstract (sentence 11) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 8382915, abstract (sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 8382915, abstract (sentences 3-5) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 8, 2026 · evidence through November 8, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).